Case Report: Camrelizumab plus gemcitabine followed by concurrent chemoradiation for HPV-positive and PD-L1-positive tonsillar squamous cell carcinoma
Modality treatment including surgery, chemotherapy, radiation and immunotherapy was considered as standard strategy for tonsillar squamous cell carcinoma (TSCC). We reported a case of a 78-year-old man under severe underlying medical conditions who diagnosed with human papillomavirus (HPV)-positive...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1528198/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Modality treatment including surgery, chemotherapy, radiation and immunotherapy was considered as standard strategy for tonsillar squamous cell carcinoma (TSCC). We reported a case of a 78-year-old man under severe underlying medical conditions who diagnosed with human papillomavirus (HPV)-positive and programmed death ligand 1 (PD-L1)-positive TSCC. He was administered camrelizumab combined with gemcitabine (GEM) for 8 cycles with partial response. Then, we gave him concurrent nanoparticle albumin-bound paclitaxel (nab-paclitaxel)-based chemoradiation. Eventually, this patient achieved complete response without severe adverse events. After a 12-month follow-up, he had no recurrence or metastasis. |
|---|---|
| ISSN: | 1664-3224 |